Prostate cancer (PCa), one of the current world’s major health concerns has the highest incidence of any type of cancer. It is the 2nd most common type of cancer and the 5th most frequent cause of cancer-related death in men worldwide. PCa develops after the age of fifty in men. Unfortunately, many patients do not have indications, they don’t take treatment & 2/3rd of cases of PCa grow slowly. High-risk tumour predicts prostate-specific antigen (PSA) levels ≥20ng/mL, stage T3-T4 disease, or Gleason scores ≥7. These characteristics are represented by 20-30% of PCa patients.
Hormone therapy & external beam radiotherapy alone are found to be effective and acceptable methods in locally advanced PCa. Both methods have certain side effects.
• Frequent urge to urinate, dysuria, nocturia & genitourinary irritation
• Enhanced desire to defecate & rectal mucus passage or bleeding
• Raise in risk of development of secondary malignancies in 10-15 years
• Palpitation, hot flashes, headache, tiredness, fatigue & gynecomastia
• Libido loss & erectile dysfunction
• Weight gain or loss of muscle mass
• Mood swings, depression & impaired vision
• Cardiac attack & stroke
Treatment of high-risk PCa is not easy due to its poorer interpretation. One of the chief therapies for enlarged prostrate (>60 mL) is a combination of radiation therapy and hormone therapy.
Neoadjuvant therapy includes hormone therapy, simultaneously adjuvant therapy of percutaneous radiation is provided. Androgen receptor blockers like bicalutamide or gonadotropin-releasing.
hormone & agonists like goserelin or antagonists like degarelix are also prescribed. Hormone therapy sterilizes occult metastases & radiation kills tumor cells irrespective of hormone sensitivity in cumulative cooperation. This unique combination offers 1. Increasing dose allowance with low toxicity offers prostatic volume debulking 2. Enhanced radiosensitivity due to tumor hypoxia reduction 3. Decrease cell repopulation during radiation therapy because of cell cycle slowing 4. Immunomodulation-induced apoptosis and direct effect on tumour cells 5. Supra-additive effect The advantages of combination therapy include better biochemical regulation, up to 50% drop in prostate volume, cancer-specific & relapse-free survival & overall improved survival benefits & lowered cancer reappearance and positive influence on total mortality & disease-specific mortality rate.
Combination therapy of radiation & hormone therapy in PCa requires more focused clinical trials in order to make it more suitable & usable. Simultaneously detailed patient investigation records including the onset of PCa, evolution, statin intake, diet habits & patterns, daily lifestyle, weight & body mass index, smoking and PCa screening type needs to be maintained. A combination of radiation & hormone therapy can be used as a remedy choice for moderate to high-risk localized PCa patients but the benefit is still not very clear in low-risk PCa patients. While using the combination therapy side effects should be managed efficiently and promptly.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Insurance Claim Denials for Preventive Care More Common in At-Risk Patients
2.
Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models
3.
A Lot Can Be Said About You by Including Yourself in Photos.
4.
Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco
5.
Study finds higher breast cancer rates in areas with more air pollution
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Understanding Waldenstrom Macroglobulinemia - A Comprehensive Guide
3.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
4.
Managing Acute Respiratory Failure in Hematological Malignancies
5.
Exploring the Role of Fecal Leukocytes in Intestinal Health
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
3.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation